Mark Graber, PhD, JD
Professor Mark A. Graber held a faculty position in the Department of Government and Politics at the University of Maryland, College Park, from 1993 to 2007 and taught at the University of Maryland School of Law as an adjunct professor beginning in the fall of 2002. In 2004, he was appointed Professor of Government and Law at Maryland Carey Law, a title he held until May 1, 2015, at which time he received an appointment as the Jacob A. France Professor of Constitutionalism.In 2016, he was named Regents Professor, one of only seven Regents Professors in the history of the University System of Maryland and the only Regents Professor on the UMB campus. He served as associate dean for research and faculty development from 2010 to 2013. He has also been one of the organizers of the annual Constitutional Law "Schmooze," which attracts scholars from across the country to the law school. Professor Graber is recognized as one of the leading scholars in the country on constitutional law and politics.He is the author of A New Introduction to American Constitutionalism (Oxford 2013), Dred Scott and the Problem of Constitutional Evil (Cambridge, 2006), and co-editor (with Keith Whittington and Howard Gillman) of American Constitutionalism: Structures and Powers and American Constitutionalism: Rights and Powers, both also from Oxford University Press, and co-editor with Mark Tushnet and Sandy Levinson of Constitutional Democracy in Crisis (Oxford 2018).His most recent book is Punish Treason, Reward Loyalty: The Forgotten Goals of Constitutional Reform After the Civil War (Kansas, 2023). Professor Graber is also the author of over 100 articles, including "The Non-Majoritarian Problem: Legislative Deference to the Judiciary" in Studies in American Political Development, "Naked Land Transfers and American Constitutional Development," published in the Vanderbilt Law Review and "Resolving Political Questions into Judicial Questions: Tocqueville’s Aphorism Revisited," published by Constitutional Commentary. He has been a visiting faculty member at Harvard University, Yale Law School, the University of Virginia School of Law, the University of Pennsylvania, the University of Toronto, the University of Oregon School of Law, and Simon Reichman University.For interview requests, please contact the Office of Communications and Public Affairs: https://www.umaryland.edu/news/for-the-mediaThis information was last updated February 19, 2024.
More from Youtube
- 0:56Could Weight-Loss Drugs Curb Cravings for Addictive Substances? | Breakthroughs Can’t WaitEveryone has heard of Ozempic and Wegovy for treating diabetes and weight loss. But, what's been discovered in clinical trials, is an anti-craving effect is showing promising results for those battling alcohol and drug addiction.At the University of Maryland, Baltimore, researchers are exploring how GLP-1 receptor agonists — a class of drugs commonly used for weight loss — may offer new hope for people with cocaine use disorder. This is just one example of how federally funded research at UMB is Changing The Future Today.Hear from Sarah Kattakuzhy, MD, co-director for the Research Initiative on Infectious Disease and Substance Use Disorder, at the University of Maryland School of Medicine explains. Kattakuzhy is also the associate director of the Kahlert Institute for Addiction Medicine.๐งช Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.๐ Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs #BreakthroughsCantWait #NIHfunding #CocaineUseDisorder #GLP1 #AddictionResearch #UMB #ResearchMatters
- 0:55Confronting the 4th Wave of the Drug Overdose Death Crisis | Breakthroughs Can't WaitOpioid and cocaine use epidemic is entrenched within Baltimore city, and there are no FDA-approved treatment for any stimulant disorders.At the University of Maryland, Baltimore, researchers are exploring how GLP-1 receptor agonists — a class of drugs commonly used for weight loss — may offer new hope for people with cocaine use disorder. This is just one example of how federally funded research at UMB is Changing The Future Today.Hear from Sarah Kattakuzhy, MD, co-director for the Research Initiative on Infectious Disease and Substance Use Disorder, at the University of Maryland School of Medicine explains. Kattakuzhy is also the associate director of the Kahlert Institute for Addiction Medicine.๐งช Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.๐ Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs #BreakthroughsCantWait #NIHfunding #CocaineUseDisorder #GLP1 #AddictionResearch #UMB #ResearchMatters
- 0:45Can a Weight-Loss Drug Help Treat Cocaine Addiction? | Breakthroughs Can’t WaitCan a weight-loss drug help treat cocaine addiction?At the University of Maryland, Baltimore, researchers are exploring how GLP-1 receptor agonists — a class of drugs commonly used for weight loss — may offer new hope for people with cocaine use disorder. This is just one example of how federally funded research at UMB is Changing The Future Today.Hear from Sarah Kattakuzhy, MD, co-director for the Research Initiative on Infectious Disease and Substance Use Disorder, at the University of Maryland School of Medicine explains. Kattakuzhy is also the associate director of the Kahlert Institute for Addiction Medicine.๐งช Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.๐ Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs #BreakthroughsCantWait #NIHfunding #CocaineUseDisorder #GLP1 #AddictionResearch #UMB #ResearchMatters
- 4:53Changing the Future of Addiction Care | Breakthroughs Can’t Wait with Dr. Sarah KattakuzhyCan a class of drugs best known for treating diabetes and weight loss also help people struggling with cocaine use disorder?Dr. Sarah Kattakuzhy, an associate professor at the University of Maryland School of Medicine, is leading innovative research on GLP-1 receptor agonists — medications that may offer a new path forward in treating addiction.This NIH-funded research could transform how we understand and address substance use, giving people more options — and more hope.๐งช Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.๐ Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs#BreakthroughsCantWait #AddictionResearch #CocaineUseDisorder #GLP1 #SubstanceUseDisorder #UMBResearch #NIHfunding #HealthInnovation #DrSarahKattakuzhy
- 4:24UMB's 13th Annual Interprofessional Education DayHosted by the University of Maryland Baltimore's Center for Interprofessional Education (CIPE) on April 2, IPE Day brought together more than 170 students from all seven UMB professional schools — including medicine, nursing, pharmacy, law, dentistry, physical therapy, social work, and the Graduate School — for a full afternoon of collaborative learning, simulation activities, and real-life insights into the power of team-based care.Read more: https://www.umaryland.edu/news/archived-news/april-2025/ipe-day-centers-on-listening-to-patients-and-peers.php
- 59:34Virtual Face to Face: The Challenges Facing Academic ResearchThe changes and challenges facing academic research and the University of Maryland, Baltimore's response was the topic of Virtual Face to Face on April 10 hosted by James Hughes, MBA, Chief Enterprise and Economic Development Officer and Senior Vice President. Hughes was joined by University of Maryland School of Medicine Professor and Executive Vice Dean Chris O’Donnell, PhD, and E. Albert Reece, MD, PhD, MBA, Director of the Center for Advanced Research Training and Innovation.